19:36 , Jan 19, 2018 |  BC Week In Review  |  Clinical News

Albireo gets $55M for elobixibat approval in Japan

Albireo Pharma Inc. (NASDAQ:ALBO) nearly doubled its cash reserves after Japan’s Ministry of Health, Labour and Welfare (MHLW) approved Goofice elobixibat to treat chronic constipation. The approval triggered about $55 million in payments to the...
16:26 , Jan 19, 2018 |  BC Extra  |  Company News

Albireo receives $55M for elobixibat approval in Japan

Albireo Pharma Inc. (NASDAQ:ALBO) nearly doubled its cash reserves after Japan’s Ministry of Health, Labour and Welfare (MHLW) approved Goofice elobixibat on Friday to treat chronic constipation. The approval triggered about $55 million in payments...
18:37 , Nov 17, 2017 |  BC Week In Review  |  Clinical News

Albireo reports Phase II data for A4250 in cholestatic liver disease

Albireo Pharma Inc. (NASDAQ:ALBO) said A4250 was well tolerated and led to no treatment-related serious adverse events in a Phase II trial in 20 patients ages 1-17 with cholestatic liver disease, including progressive familial intrahepatic...
12:26 , May 26, 2017 |  BC Week In Review  |  Financial News

Albireo raises $45.1M in follow-on

On May 24, Albireo Pharma Inc. (NASDAQ:ALBO) raised $45.1 million through the sale of 2.2 million shares at $20.50 in a follow-on underwritten by Cowen, William Blair, Needham and Wedbush PacGrow. Next half, Albireo plans...
22:53 , May 24, 2017 |  BC Extra  |  Financial News

Follow-on roundup: Alnylam, GlycoMimetics, Albireo

Alnylam Pharmaceuticals Inc. (NASDAQ:ALNY), GlycoMimetics Inc. (NASDAQ:GLYC) and Albireo Pharma Inc. (NASDAQ:ALBO) all priced follow-ons Wednesday, raising a combined $485 million. Alnylam raised $359.4 million via the sale of 5 million shares at $71.87 in...
22:50 , Nov 17, 2016 |  BC Week In Review  |  Company News

Biodel, Albireo deal

Albireo and Biodel merged to form Albireo Pharma Inc. (NASDAQ:ALBO, Boston, Mass.). The company plans to start a pivotal trial of lead compound A4250 next year to treat progressive familial intrahepatic cholestasis (PFIC). A4250 is...
07:00 , Oct 31, 2016 |  BC Week In Review  |  Clinical News

A4250 regulatory update

EMA granted PRIority MEdicines (PRIME) designation to A4250 from Albireo to treat progressive familial intrahepatic cholestasis. A4250 is in Phase II testing for pediatric chronic cholestasis. The product is an inhibitor of solute carrier family...
08:00 , Feb 23, 2015 |  BC Week In Review  |  Clinical News

A4250: Phase IIa started

Albireo began an open-label, crossover, Swedish Phase IIa trial to evaluate 1.5-3 mg oral A4250 once daily for 4 weeks in about 12 patients with PBC and cholestatic pruritus. Albireo AB , Gothenburg, Sweden  ...
07:00 , Jun 20, 2013 |  BC Innovations  |  Distillery Therapeutics

Indication: Endocrine/metabolic disease

Indication Target/marker/pathway Summary Licensing status Publication and contact information Endocrine/metabolic disease Diabetes Solute carrier family 10 sodium-dependent bile acid transporter member 2 (SLC10A2; ASBT; IBAT) In vitro and rodent studies identified benzothiazepine ASBT inhibitors that...
08:00 , Nov 12, 2012 |  BC Week In Review  |  Clinical News

A4250 regulatory update

FDA granted Orphan Drug designation to Albireo's A4250 to treat progressive familial intrahepatic cholestasis (PFIC) and primary biliary cirrhosis (PBC). The company plans to move the compound, an inhibitor of solute carrier family 10 sodium-dependent...